News

Lupin launches Posaconazole delayed-release tablets

Posaconazole delayed-release tablet is a generic equivalent of Noxafil delayed-release tablet, of Merck Sharp & Dohme Corp

Lupin has launched Posaconazole delayed-release tablets, used for prevention of invasive aspergillus and candida infections in patients at high risk due to low level of immunity.

THIS CAN BE YOUR ADVERTISEMENT

Posaconazole delayed-release tablet is a generic equivalent of Noxafil delayed-release tablet, of Merck Sharp & Dohme Corp.

In a regulatory filing, Lupin announced the launch of Posaconazole delayed-release tablets, 100 mg, after its alliance partner AET Pharma US Inc (part of Tiefenbacher Group) received approval for its abbreviated new drug application (ANDA) from the United States Food and Drug Administration.”

Quoting IQVIA moving annual total (MAT) data for December 2020, Lupin said Posaconazole delayed-release tablets, 100 mg, had estimated annual sales of $186 million in the US.

PTI

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close